Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• The COVID-19 pandemic caused significant global health and economic disruption.
• Rapid advancements in vaccine technology, including genetic sequencing of SARS-CoV-2, have led to the development of numerous vaccine candidates.
• Viral vector-based vaccines have emerged as a significant area of development in recent years.

Purpose of the Study:

• To review the development of adenoviral vector-based vaccines for COVID-19 management.
• To summarize the status of these vaccines, including those under emergency use authorization (EUA) and in various developmental stages.

Main Methods:

• Review of scientific literature and regulatory approvals for COVID-19 vaccines.
• Focus on adenoviral vector vaccine technology.
• Analysis of vaccine candidates as of April 2022.

Main Results:

• Adenoviral vectors are effective vaccine carriers due to high yield, safety, efficacy, and manageable logistics.
• As of April 2022, three adenoviral vector-based vaccines were among the 10 approved by the WHO for COVID-19.
• These vaccines elicit a strong immune response, potentially reducing the need for boosters.

Conclusions:

• Non-replicating adenoviral vectors represent a promising platform for infectious disease vaccines.
• Adenoviral vector vaccines are a key component of the global strategy for COVID-19 management.
• Continued development and deployment of these vaccines are crucial for pandemic control.